Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease
Risankizumab treatment resulted in reduced rates of CD-related hospitalization with treatment effect observed within 12 weeks of randomization.
Authors
- Remo Panaccione (ORCID: https://orcid.org/0000-0002-5247-940X)
- Wan‐Ju Lee (ORCID: https://orcid.org/0000-0001-9263-6943)
- Kristina Kligys
- Jasmina Kalabic (ORCID: https://orcid.org/0009-0007-4698-1042)
- Edward V. Loftus (ORCID: https://orcid.org/0000-0001-7199-6851)
- Stefan Schreiber
- Marc Ferrante
- Takehiro Arai (ORCID: https://orcid.org/0000-0003-2077-2684)
- Xiaomei Liao
- Laurent Peyrin-Biroulet
- Jenny Griffith
- Brian G. Feagan
- Si Xuan
Institutions
- Western University (CA)
- Mayo Clinic (US)
- Inserm (FR)
- University of Calgary (CA)
- AbbVie (United States) (US)
- University Hospital Schleswig-Holstein (DE)
- Clinique Hartmann (FR)
- Clinique Ambroise Paré (FR)
- Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
- Komatsu (Japan) (JP)
- Université de Lorraine (FR)
- University of Lübeck (DE)
- KU Leuven (BE)
Publication Details
- Journal
- Gastro Hep Advances
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1016/j.gastha.2024.100603
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.10
Funders
- AbbVie